Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)

NCT02221739 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Ipilimumab
RADIATION: Radiotherapy (IMRT or 3-D CRT)

Sponsor

NYU Langone Health

Collaborators

[object Object]